New combo aims to stall aggressive brain tumors when surgery and radiation fail

NCT ID NCT06126588

Recruiting now Disease control Sponsor: Central Hospital, Nancy, France Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase IIb trial tests whether combining the drug everolimus with a targeted radiation therapy (177Lu-DOTATATE) can slow tumor growth in people with grades 2 and 3 meningioma that no longer responds to surgery or radiation. About 28 adults will receive the combination for 7 months. The main goal is to see how long the tumor stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: everolimus and 177Lu-DOTATATE
What this could lead to: If successful, this combination could offer a new treatment option that slows tumor growth and extends survival for people with aggressive, hard-to-treat meningioma.
What could go wrong: This is a small, early-phase trial with only 28 participants. The combination may not work better than existing options, and side effects from the drugs could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MENINGIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

grade II meningioma grade III meningioma meningioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MENINGIOMA

Contacts and locations

Locations

CHRU of Nancy
NOT_YET_RECRUITING

Vandœuvre-lès-Nancy, Grand Est, 54511, France
Nancy Hospital
RECRUITING

Vandœuvre-lès-Nancy, 54511, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.